There needs to be a national dialogue on how can we reach a point where our dollars are used wisely, patients get what they need, and we all get the innovation that we want, said Robert Dubois, MD, PhD, chief science officer and executive vice president, National Pharmaceutical Council.
There needs to be a national dialogue on how can we reach a point where our dollars are used wisely, patients get what they need, and we all get the innovation that we want, said Dr Robert Dubois, MD, PhD, chief science officer and executive vice president, National Pharmaceutical Council.
Transcript (slightly modified)
How will Going Below the Surface address the question of how well do we spend when it comes to healthcare? How will this help give an understanding to what’s driving healthcare spending?
We believe there is a national dialogue that needs to be occur, and a national dialogue that’s quite different than the 1 we’ve had in the past. For decades, we’ve had finger pointing exercises: “This is too expensive, this is causing the rise in expenditures, and if we’d only solve this problem, we’d have it resolved.”
The reality is, it’s an extensive and a difficult dialogue. Going Below the Surface initiative is really to do that, and to being to have those really tough questions talked about, looking at the costs, not just of drugs or hospitals, but also of devices and seeing specialists rather than primary care doctors or the lack of focus on social determinants. It’s really having that broad dialogue, and to not just look at the costs and pointing those fingers, but rather looking at the costs and benefits, and trying to very carefully say: “What would be best? How can we reach a point where our dollars are used wisely, patients get what they need, and we all get the innovation that we want.”
The Going Below the Surface initiative is really an opportunity to talk and reach that end of the journey.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More